Common bisphosphonates in cancer care

Bones constantly undergo removal and replacement of mineral. Bisphosphonates attach to bone and reduce the activity of cells that break it down. In oncology, they may help when cancer has affected bone, when multiple myeloma is damaging bone, or when treatment contributes to bone loss. They can also help lower a dangerously raised blood calcium level caused by cancer.

Zoledronic acid and pamidronate are commonly delivered into a vein. Other bisphosphonates can be taken by mouth in selected settings. Denosumab is another bone-strengthening drug, but it works differently and is not a bisphosphonate.

Tell the oncology team about kidney problems, dental symptoms, planned dental work, swallowing difficulties, and every medicine or supplement you use. Blood tests help the team check kidney function and mineral levels before treatment. A dental review may be advised because exposed or infected jawbone is an uncommon but serious complication.

Follow the prescribed advice on fluids, calcium, and vitamin D rather than starting supplements independently. After an infusion, temporary feverishness, aching, or fatigue can occur. Keep the treatment contact number available and record symptoms that persist or interfere with eating, drinking, or normal movement.

Contact the treatment team promptly for new jaw pain, gum swelling, a loose tooth, an unhealed mouth sore, or exposed bone in the mouth. Urgent assessment is appropriate for muscle spasms, tingling around the mouth, marked weakness, reduced urine output, severe vomiting, breathing difficulty, or facial swelling. Report new thigh or groin pain as well, particularly if it worsens when bearing weight.

Ask why a bisphosphonate is recommended in your situation, how it will be given, and which blood tests are required. Confirm what to do before dental treatment, whether prescribed supplements are needed, how kidney function affects the choice, and which symptoms should delay the next dose.